Announcement
Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd (NSE: PPLPHARMA, BSE: 543635), announced on 4 August 2026 that it has launched a state‑of‑the‑art spray‑drying suite at its dedicated peptide development and manufacturing facility in Turbhe, India.
Facility Details
The new suite features Band 5 containment capacity and is equipped with its own air‑handling units, nitrogen supply, and dedicated control systems. It operates as a closed‑loop system with an inert‑gas supply, specialized HVAC, air‑locked entries and exits, operator isolation, and a dedicated cleaning area, allowing safe handling of potent compounds and organic solvents. The processing area maintains ISO Class 8 (Class 100,000) cleanliness standards throughout operations.
Technical Capabilities
Designed for small‑volume, high‑potency batches, the unit supports a feed rate of up to 1 liter per hour and can spray‑dry highly concentrated solutions containing up to 30 % water. While optimized for peptides, HPAPIs and other biomolecules, the suite can also be leveraged for low‑volume small‑molecule formulations under optimal conditions. Spray drying converts liquid formulations into dry powders in a single step, improving bioavailability, achieving precise particle size, and enabling safe processing of temperature‑sensitive compounds.
Strategic Significance
Dr Jordi Bacardit, Global Technical Lead on Peptides and Member of the Science Collective at PPS, stated that peptides present intricate formulation challenges due to instability and sensitivity, and that the new spray‑drying capability allows tight control over temperature and solvent environment, helping partners bring stable, high‑quality peptide formulations to patients worldwide.
Company Background
PPS offers end‑to‑end development and manufacturing services across the drug life cycle, with a globally integrated network of facilities in North America, Europe, and Asia. Services include drug discovery, process development, clinical trial supplies, commercial API supply, finished dosage forms, highly potent APIs, antibody‑drug conjugates, sterile fill/finish, peptide products, and potent solid oral drugs. PPS also provides biologics development and manufacturing through its associate Yapan Bio Private Limited.
Piramal Pharma Ltd operates 17 global development and manufacturing facilities and a distribution network in over 100 countries. Its portfolio includes PPS, Piramal Critical Care (hospital generics), and Piramal Consumer Healthcare (OTC products). An associate, Abbvie Therapeutics India Private Limited (a joint venture with Abbvie), is a market leader in ophthalmology, and the group holds a strategic minority investment in Yapan Bio Private Limited, which focuses on biologics, vaccines, and gene therapies.
Disclaimer: This press release is distributed under an arrangement with PRNewswire; PTI takes no editorial responsibility.